lazabemide
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
To evaluate whether lazabemide has proarrhythmic or hypotensive potency in Parkinson's disease (PD), we conducted an 8-week…
AIMS
The objectives of this study were to assess the tolerability, pharmacokinetics and pharmacodynamics of the reversible…
The objective of this study was to assess the tyramine pressor sensitivity during combined administration of selective and…
SummarySpecific inhibitors of monoamine oxidase type B (MAO-B) constitute a novel and expanding pharmacological class. At present…
1. Single oral doses (100-300 mg) and multiple oral doses (100-350 mg 12 hourly for 7 days) of lazabemide were administered to 35…
BACKGROUND
Lazabemide (Ro 19-6327) is a short-acting, reversible, highly selective inhibitor of monoamine oxidase type B, that…